Aurora Kinase
The Aurora kinases comprise a family of evolutionary conserved serine/threonine kinases (Aurora-A, Aurora-B, and Aurora-C). Aurora kinases control multiple events during cell cycle progression and are essential for mitotic and meiotic bipolar spindle assembly and function.
Aurora-A, Aurora-B, and Aurora-C share a highly conserved kinase domain but have quite different subcellular localizations and functions during mitosis. Aurora-A mostly controls centrosome maturation and bipolar spindle assembly, while Aurora-B and Aurora-C are required for condensation, attachment to kinetochores, and alignment of chromosomes during (pro-)metaphase and cytokinesis. In human tumors, all Aurora kinase members play oncogenic roles related to their mitotic activity and promote cancer cell survival and proliferation. Inhibitors targeting Aurora kinases have attracted attention in cancer research.
Aurora Kinase Isoform Specific Products
All Product Categories
-
Aurora Kinase Related Products (229)
Related Products (229)
-
Antibodies (4)
-
Aurora Kinase Isoform Comparison
-
VEGFR-2/AURKA-IN-1
0 ImagesCat. No.: HY-155464VEGFR-2/AURKA-IN-1 (compound 5e) is a thiazolidin-4-one derivative with antiglioma activity (IC50: 6.43 μM, LN229). VEGFR-2/AURKA-IN-1 has affinity for AURKA and VEGFR-2 and is a potential ligand. VEGFR-2/AURKA-IN-1 causes DNA strand breaks and exhibits cytotoxic and anticancer potential.
-
AURKA-IN-4
0 ImagesAURKA-IN-4 (compound 13), a capsaicin-derived prohibitin ligand, is an AURKA inhibitor. AURKA-IN-4 acts as a molecular glue within the AURKA/PHB2/LC3 complex. AURKA-IN-4 is specific to the mitochondrial pool of AURKA, and inhibits AURKA-dependent mitophagy. AURKA-IN-4 can be used for cancer research.
-
FAK-IN-22
0 ImagesCat. No.: HY-168718CAS No.: 2703920-02-7FAK-IN-22 (Compound 26) is an inhibitor of FAK, JAK3, and Aurora B, with IC50 values of 50.94 nM, 9.99 nM, and 0.49 nM, respectively, effectively inhibiting tumor occurrence and metastasis in pancreatic ductal adenocarcinoma (PDAC). FAK-IN-22 effectively inhibits the proliferation of PANC-1 cells, with an IC50 value of 0.15 μM. FAK-IN-22 induces apoptosis and G2/M phase arrest in PANC-1 cells by inhibiting the FAK/PI3K/Akt signaling pathway.
-
Aurora kinase inhibitor-14
0 ImagesCat. No.: HY-158618CAS No.: 958226-81-8Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of Aurora kinases with IC50 values of 0.5 nM and 1.2 nM for Aurora A and Aurora B, respectively. Aurora kinase inhibitor-14 binds to the ATP-binding site of Aurora kinases to block chromosome segregation during mitosis and induce apoptosis in tumor cells. Aurora kinase inhibitor-14 is promising for research of various solid tumors and hematological malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia.
-
KW-2450 tosylate
0 ImagesCat. No.: HY-19565CAS No.: 1360433-93-7KW-2450 tosylate is an orally active Aurora A and B kinases, IGF-1R, and IR tyrosine kinases inhibitor. KW-2450 tosylate induces Apoptosis. KW-2450 tosylate also exhibits anticancer activity against triple-negative breast cancer.
-
AURKA Human Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS01266AURKA Human Pre-designed siRNA Set A contains three designed siRNAs for AURKA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
Aurora kinase inhibitor-12
0 ImagesCat. No.: HY-149694Aurora kinase inhibitor-12 (Compound 1a ) is the inhibitor of aurora kinase which is a key enzyme that is implicated in tumor growth.
-
Aurora kinase-IN-1
0 ImagesCat. No.: HY-115932Aurora kinase-IN-1 (Compound 9) is a potent inhibitor of aurora kinase. Aurora kinase-IN-1 upregulates the expression of G1 cell cycle inhibitory proteins including p21 and p27, and G1 progressive cyclin D1, and downregulates G1-to-S progressive cyclins, resulting in cell cycle arrest at the G1/S boundary. Aurora kinase-IN-1 also induces apoptosis. Aurora kinase-IN-1 is a lead compound for chemotherapeutic agents.
-
(E/Z)-HOI-07
0 ImagesCat. No.: HY-125158ACAS No.: 1606160-40-0(E/Z)-HOI-07 is a potent and selective Aurora B inhibitor. HOI-07 has antitumor activity.
-
Aurora A inhibitor 2
0 ImagesCat. No.: HY-146037CAS No.: 2412144-74-0Aurora A inhibitor 2 (Compound 16h) is a potent Aurora A kinase inhibitor with an IC50 of 21.94 nM. Aurora A inhibitor 2 induces caspase-dependent apoptosis in MDA-MB-231 cells.
-
GSK-1070916 (GMP)
0 ImagesCat. No.: HY-70044GCAS No.: 942918-07-2Synonyms: GSK-1070916A (GMP)GSK-1070916 (GMP) is GSK-1070916 (HY-70044) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-1070916 is a potent and selective ATP-competitive inhibitor of aurora B and aurora C with Kis of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A.
-
AURKC Rat Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS01275AURKC Rat Pre-designed siRNA Set A contains three designed siRNAs for AURKC gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
GW814408X
0 ImagesCat. No.: HY-160691CAS No.: 886599-05-9GW814408X is a kinase chemical genome group (KCGS) compound that inhibits the AURKC kinase involved in cell cycle progression, checkpoint regulation, and cell division. GW814408X exhibits cell line-dependent toxicity, e.g., cytotoxic effects on HeLa cells. GW814408X acts as a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential implications for Fluc reporter assays.
-
PROTAC AURKA degrader 1
0 ImagesCat. No.: HY-175830PROTAC AURKA degrader 1 (Compound A16 + X7) is a Aurora kinase A (AURKA) PROTAC degrader. PROTAC AURKA degrader 1 can be used for cancers research. Pink: AURKA ligand (HY-175827); Blue: CRBN ligase ligand (HY-W867704); Black: linker (HY-132208)
-
AURKC Human Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS01273AURKC Human Pre-designed siRNA Set A contains three designed siRNAs for AURKC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
AURKA against 1
0 ImagesCat. No.: HY-162837AURKA against 1 is an inhibitor of AURKA (IC50 less than 0.5 nM), targeting endogenous lysine (K162) acetylation, and has anti-proliferation activity against tumor cells. AURKA against 1 induces K162 acetylation, and the kinase activity of AURKA is reversibly restored in HCT116 cells transfected with SIRT3.
-
CG-1521
0 ImagesCat. No.: HY-108919CAS No.: 674767-29-4CG-1521 is a histone deacetylase (HDAC) inhibitor that stabilizes Ac-Lys373 P53, increases P21 levels and HDAC2 degradation. CG-1521 can inhibit proliferation, induce cell cycle arrest and apoptosis. CG-1521 promotes Bax translocation to the mitochondria and cleavage. CG-1521 downregulates KIF4, Aurora B and Nek2 protein expression and DNA synthesis. CG-1521 can be used for the research of prostate cancer and inflammatory breast cancer.
-
Retreversine
0 ImagesCat. No.: HY-113894CAS No.: 1028332-91-3Retreversine is an inactive control for Reversine. Reversine is a novel class of ATP-competitive Aurora kinase inhibitor.
